Transthoracic echocardiography findings
Implications for clinical management

Background
Transthoracic echocardiography (TTE) is commonly used for the evaluation of suspected or known cardiac disease.

Objective
This article discusses the impact of TTE findings on patient management using seven case studies as examples.

Discussion
Any abnormality on echocardiography should be carefully considered as to its severity, cause and potential to account for the patient’s symptoms. Evidence based therapies should be instituted in the setting of a reduced left ventricular ejection fraction and previously unrecognised myocardial infarction. Other abnormalities such as left ventricular hypertrophy or diastolic abnormalities suggest the need for more aggressive risk factor control. Patients should be referred to a cardiologist for further evaluation if the cause of TTE abnormalities or overall diagnosis is uncertain or the patient needs ongoing monitoring and treatment.

Keywords
diagnostic imaging; heart disease, hypertension

Since its development in the 1960s, transthoracic echocardiography (TTE) has proven to be an invaluable tool for the assessment of cardiac structure and function in real-time. Due to its increasing accessibility, the number of TTEs requested in Australia has been rising, with over 600,000 TTEs performed in Australia from July 2011 to June 2012.\(^1\)

Echocardiography is appropriate for use in patients with known or suspected cardiac pathology. Findings on TTE can provide valuable diagnostic and prognostic information that may impact significantly on clinical management. However, an understanding of the significance of such findings is necessary in order to trigger appropriate clinical decision making or to implement evidence based therapies.

Echocardiography should not generally be used as a screening tool in asymptomatic patients in primary care. However, as is the case in other imaging modalities, there is the potential for incidental findings in the patient referred for an unrelated indication or with symptoms out-of-keeping with the degree of reported abnormality. This article discusses the impact of TTE findings on patient management using seven case studies as examples.

Case study 1
An asymptomatic 76-year-old man is found to have a soft systolic murmur on routine examination. The rest of his cardiovascular examination is normal. Apart from his age, he has no significant risk factors for cardiovascular disease. He is referred for a TTE, which shows that his left ventricular systolic function is depressed, with a globally reduced ejection fraction of 30%, but no valvular pathology.

Since its development in the 1960s, transthoracic echocardiography (TTE) has proven to be an invaluable tool for the assessment of cardiac structure and function in real-time. Due to its increasing accessibility, the number of TTEs requested in Australia has been rising, with over 600,000 TTEs performed in Australia from July 2011 to June 2012.\(^1\)

Echocardiography is appropriate for use in patients with known or suspected cardiac pathology. Findings on TTE can provide valuable diagnostic and prognostic information that may impact significantly on clinical management. However, an understanding of the significance of such findings is necessary in order to trigger appropriate clinical decision making or to implement evidence based therapies.

Echocardiography should not generally be used as a screening tool in asymptomatic patients in primary care. However, as is the case in other imaging modalities, there is the potential for incidental findings in the patient referred for an unrelated indication or with symptoms out-of-keeping with the degree of reported abnormality. This article discusses the impact of TTE findings on patient management using seven case studies as examples.
ventricular systolic dysfunction is a common endpoint of a range of cardiac pathologies. A list of potential causes is shown in Table 1.

Patients presenting with symptomatic HF-REF are at increased mortality risk due to progressive heart failure or ventricular tachyarrhythmias, despite advances in pharmacological and device management. An increase in mortality risk due to progressive heart failure, despite advances in pharmacological and device management. An increase in mortality risk due to progressive heart failure, despite advances in pharmacological and device management.

The finding of a reduced LVEF in a patient presenting with shortness of breath confirms the diagnosis of HF-REF. In these cases, standard heart failure therapy should be initiated. In addition, in patients incidentally found to have a reduced ejection fraction of <50%, an angiotensin converting enzyme inhibitor (ACEI) should be commenced in order to prevent progression to symptomatic heart failure, as this reduces mortality over the long term. In patients who progress to symptomatic heart failure, as this reduces mortality over the long term.

Case study 2
A 60-year-old man with a past history of type 2 diabetes and hypercholesterolaemia presents with shortness of breath. He describes no other cardiac or respiratory symptoms. He takes metformin 850 mg twice per day and atorvastatin 20 mg/day. Cardiorespiratory examination is normal and full blood examination and urea, creatinine and electrolytes are also normal. His electrocardiogram (ECG) shows inferior T wave inversion. He is referred for a TTE, which shows an old inferior myocardial infarct with scar formation and a normal LVEF. A stress echocardiogram reveals hypokinesis in the territory of the left anterior descending artery following exercise. A coronary angiogram shows triple vessel disease and the patient is referred for coronary artery bypass surgery.

Discussion
Regional variation in left ventricular wall motion, either at rest or during stress, is strongly suggestive of ischaemic heart disease. There may be areas of hypokinesia (decreased myocardial thickening), akinesia (no thickening), dyskinesia (paradoxical motion) or prior infarction with scar formation. Patients with ischaemic heart disease may present with classic angina pain, atypical features or, as in Case 2, an ‘anginal equivalent’ such as exertional dyspnoea. Patients may also present with heart failure symptoms due to an ischaemic cardiomyopathy. Resting TTE may be helpful in detecting very significant regional wall motion abnormalities such as previous infarction, but stress echocardiography is far more sensitive in detecting areas of myocardial ischaemia.

Approximately one-quarter of myocardial infarctions remain unrecognised and may be an incidental finding on TTE at a later stage. These ‘silent’ myocardial infarctions are more common in the setting of diabetes and hypertension. Regardless, the prognosis of unrecognised myocardial infarction is similar to symptomatic infarction and standard treatment for ischaemic heart disease (including aspirin, statin, beta-blocker and ACEI therapy) should be commenced.

Case study 3
An 80-year-old woman presents with two episodes of heart palpitations in the past week. She states that they felt irregular and rapid but denies other cardiac symptoms. Abnormal findings on examination include an irregular pulse and a hyperkinetic apex beat, which is displaced. She has a history of hypertension treated with telmisartan, hydrochlorothiazide and amlodipine. Full blood examination, thyroid stimulating hormone and urea, creatinine and electrolytes are normal. A 12-lead ECG confirms atrial fibrillation with a rapid ventricular rate of 120 bpm with no other significant abnormalities. A TTE reveals concentric left ventricular hypertrophy with normal LVEF.

Discussion
Transthoracic echocardiography can detect cardiac pathology resulting from chronic, suboptimally controlled hypertension, including left ventricular hypertrophy and increased left ventricular mass. Mild left ventricular dilatation or diastolic abnormalities may also be present. Atrial fibrillation is also common in the setting of hypertensive heart disease. Therefore, an echocardiogram may be indicated to evaluate for cardiac pathology associated with atrial fibrillation.

Left ventricular hypertrophy, either by voltage criteria on a 12-lead ECG or measured by echocardiography, is associated with an increased risk of symptomatic heart failure and mortality. In a patient with a history of hypertension, left ventricular hypertrophy should trigger more aggressive treatment of hypertension to achieve recommended target levels. Regression of left ventricular hypertrophy is associated with a decrease in cardiovascular events and heart failure hospitalisations.

In Case 3, a beta-blocker would serve dual functions as an additional antihypertensive agent as well as rate control for atrial fibrillation. A decision regarding the need for anticoagulation depends on clinical, not echocardiographic, parameters (see Resource).

Symmetrical hypertrophy on echocardiography may also occur in the setting of aortic stenosis, which would be seen on the same scan. However, increased left ventricular wall thickness in the absence of a history of hypertension or aortic stenosis, and usually with marked diastolic abnormalities, may suggest cardiac amyloidosis, an infiltrative disorder with a poor prognosis. In this case, or in cases where the aetiology remains unclear, referral to a cardiologist is indicated. The detailed evaluation of risk factors for sudden cardiac death, treatment of symptoms and genetic counselling for family members.

Different causes of increased left ventricular wall thickness are illustrated in Figure 1.
Transthoracic echocardiography findings – implications for clinical management

In contrast, moderate to severe abnormalities of diastolic filling are less common, found in 6% of Canberra Heart Study subjects with normal LVEF. Such abnormalities are reported on TTE as a ‘pseudonormal’ or ‘restrictive’ pattern, usually with an increased Tissue Doppler E/E ratio >15. These patterns reflect significant diastolic dysfunction with elevated left atrial pressure and are more likely to explain dyspnoea.

However, significant diastolic dysfunction may not always be seen on resting TTE. Evidence of increased filling pressures and, occasionally, alternative causes of dyspnoea such as dynamic left ventricular outflow tract obstruction, may only be apparent after stress. As in Case 4, respiratory causes such as COPD should also be considered before diagnosing HF-PEF, as the cause of dyspnoea in a former smoker. Referral to a cardiologist may be necessary if, as is frequently the case, there is some question over the diagnosis. A combination of a number of tests, including chest X-ray, echocardiography, natriuretic peptides and respiratory function may need to be considered before making a diagnosis.

Prognosis is poor in patients presenting with HF-PEF. Any abnormalities of diastolic function on TTE are associated with an increased risk of heart failure and increased mortality within the general population, which may reflect the impact of underlying conditions such as hypertension, diabetes and ischaemia on prognosis. However, there is as yet no evidence of a mortality benefit from pharmacological intervention for this condition, although improvements in exercise tolerance may be seen. Treatment of patients with abnormalities of diastolic function on TTE are associated with an increased risk of heart failure and increased mortality within the general population, which may reflect the impact of underlying conditions such as hypertension, diabetes and ischaemia on prognosis. However, there is as yet no evidence of a mortality benefit from pharmacological intervention for this condition, although improvements in exercise tolerance may be seen.21 Treatment of patients with abnormalities of diastolic function is generally directed toward control of ischaemia, optimisation of blood pressure and glycaemic control in diabetes, as well as managing comorbidities such as COPD.

Case study 5

An 84-year-old woman is found to have a systolic murmur audible over the aortic area on routine cardiac examination. She says she is not short of breath on exertion, but admits she is fairly inactive. She does not describe any other cardiac or respiratory symptoms. A TTE reveals moderate calcific aortic stenosis.
stenosis with normal LVEF (mean pressure gradient 35 mmHg, aortic valve area of 1.1 cm²).

**Discussion**

The finding of a previously undocumented cardiac murmur should prompt evaluation for suspected valvular disease. Symptomatic patients found to have at least moderate valve pathology should be referred to a cardiologist for further evaluation. In an asymptomatic patient (such as in Case 5), monitoring involves periodic clinical and TTE re-evaluation and education of the patient to recognise the early symptoms of heart failure. However, in patients with significant valvular disease who deny any symptoms but are fairly inactive, stress echocardiography may be useful in determining whether the patient is truly asymptomatic.

Regurgitant lesions tend to be better tolerated than stenotic valvular disease, and are generally associated with a more benign clinical course. Milder degrees of valvular dysfunction are associated with a better prognosis than severe lesions and progress slowly over some years. Echocardiography may therefore be performed at greater time intervals in patients with milder degrees of valvular dysfunction than in those with more severe valvular disease (Table 2). Development of symptoms should prompt re-evaluation.

Although some authors advocate early surgical intervention for subjects with asymptomatic severe valvular pathology, surgery is generally not performed until a patient develops symptoms or evidence of ventricular dysfunction. Close echocardiographic monitoring is useful in identifying echocardiographic parameters which are associated with adverse outcomes.

**Case study 6**

An asymptomatic 34-year-old Afghan refugee reports a possible history of rheumatic fever as a child and is referred for a TTE. The TTE shows mild pulmonary hypertension with an estimated right ventricular systolic pressure of 45 mmHg and normal right ventricular function. There is no evidence of rheumatic valvular disease. Left ventricular systolic and diastolic function appear normal.

**Discussion**

Pulmonary hypertension may be caused by cardiac or respiratory pathology. When identified during an echocardiogram, the sonographer will seek evidence of specific cardiac causes such as left-sided valvular disease, diastolic dysfunction and intracardiac shunts. If no cardiac causes are detected on TTE, respiratory causes such as COPD and chronic pulmonary emboli or idiopathic pulmonary arterial hypertension should be considered.

**Case study 7**

A 25-year-old asymptomatic woman from India is referred for echocardiography following a chest X-ray for immigration purposes, which revealed cardiomegaly. On TTE she is found to have right ventricular dilatation with normal right ventricular function. Colour flow imaging demonstrates an atrial septal defect with significant left to right shunting.

**Resource**


**Authors**

Jennifer Coller MBBS, FRACP, is Research Fellow, St Vincent’s Institute of Medical Research and Education, Melbourne, Victoria. jennifer.coller@svhm.org.au

Duncan Campbell MBBS, BMedSc, PhD, Grad Dip Epi Biostat, FRACP, FCSANZ, is Senior Research Fellow, St Vincent’s Institute of Medical Research, Melbourne, Victoria

Henry Krum MBBS, PhD, FRACP, FESC, Monash Centre for Cardiovascular Research and Education in Therapeutics, Melbourne, Victoria

David Prior MBBS, FRACP, PhD, FCSANZ, is Director of Non-Invasive Cardiac Imaging, St Vincent’s Hospital, Melbourne, Victoria.

Conflict of interest: David Prior has received project grant support from the NHMRC, has served on

<table>
<thead>
<tr>
<th>Table 2. Appropriate use of echocardiographic monitoring for valvular disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lesion</strong></td>
</tr>
<tr>
<td>Native valvular stenosis</td>
</tr>
<tr>
<td>Mild stenosis without change in clinical state or cardiac examination</td>
</tr>
<tr>
<td>Moderate/severe stenosis without change in clinical state or cardiac examination</td>
</tr>
<tr>
<td>Native valvular regurgitation</td>
</tr>
<tr>
<td>Mild regurgitation without change in clinical state or cardiac examination</td>
</tr>
<tr>
<td>Moderate/severe regurgitation without change in clinical state or cardiac examination</td>
</tr>
</tbody>
</table>
advisory boards for Servier and Actelion; has received funding for lectures by Boehringer
Inglehein, CSL, Merck Sharp & Dohme, AstraZeneca and Novartis and funding for travel by
Sanofi and GlaxoSmithKline. Duncan Campbell has received research support from the NHMRC
and NHF and has received funding for lectures from The Australasian Renin Academy.

Acknowledgement
St Vincent’s Institute of Medical Research is supported in part by the Victorian Government’s
Operational Infrastructure Support Program.

References